This paper provides examples of defining estimands in real-world scenarios following ICH E9(R1) guidelines. Detailed discussions on choosing the estimands and estimators can be found in our companion papers. Three scenarios of increasing complexity are illustrated. The first example is a proof-of-concept trial in major depressive disorder where the estimand is chosen to support the sponsor decision on whether to continue development. The second and third examples are confirmatory trials in severe asthma and rheumatoid arthritis respectively. We discuss the intercurrent events expected during each trial and how they can be handled so as to be consistent with the study objectives. The estimands discussed in these examples are not the only acceptable choices for their respective scenarios. The intent is to illustrate the key concepts rather than focus on specific choices. Emphasis is placed on following a study development process where estimands link the study objectives with data collection and analysis in a coherent manner, thereby avoiding disconnect between objectives, estimands, and analyses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s43441-019-00065-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A new way to address missing data in late-stage clinical trials.
Contemp Clin Trials
January 2025
Biostatistics, Gilead Sciences, Foster City, California, USA.
According to ICH E9(R1), defining the estimand comes before defining the analysis approach, and the strategies for addressing intercurrent events are key components of the estimand. With the composite strategy, the problem of missing data disappears, because it becomes part of the endpoint definition. It is this perspective that we adopt in addressing the problem of missing data.
View Article and Find Full Text PDFPrinciples for Defining Estimands in Clinical Trials-A Proposal.
Pharm Stat
August 2024
Biostatistics Methods and Outreach, Novo Nordisk A/S, Søborg, Denmark.
The ICH E9(R1) guideline outlines the estimand framework, which aligns planning, design, conduct, analysis, and interpretation of a clinical trial. The benefits and value of using this framework in clinical trials have been outlined in the literature, and guidance has been provided on how to choose the estimand and define the estimand attributes. Although progress has been made in the implementation of estimands in clinical trials, to the best of our knowledge, there is no published discussion on the basic principles that estimands in clinical trials should fulfill to be well defined and consistent with the ideas presented in the ICH E9(R1) guideline.
View Article and Find Full Text PDFHandling Partially Observed Trial Data After Treatment Withdrawal: Introducing Retrieved Dropout Reference-Base Centred Multiple Imputation.
Pharm Stat
November 2024
Medical Statistics Department, London School of Hygiene & Tropical Medicine, London, UK.
The ICH E9(R1) Addendum (International Council for Harmonization 2019) suggests treatment-policy as one of several strategies for addressing intercurrent events such as treatment withdrawal when defining an estimand. This strategy requires the monitoring of patients and collection of primary outcome data following termination of randomised treatment. However, when patients withdraw from a study early before completion this creates true missing data complicating the analysis.
View Article and Find Full Text PDFApplication of the Estimand Framework to Anesthesia Trials.
Anesthesiology
July 2024
Department of Paediatrics, Melbourne Medical School, University of Melbourne, Melbourne, Australia; Murdoch Children's Research Institute, Melbourne, Australia.
Article Synopsis
- Events like rescue medication use, treatment discontinuation, or death can affect the outcomes in randomized trials but are often not well-handled.
- The ICH E9(R1) addendum has introduced the estimand framework to better align trial goals with their design and analysis.
- This article explains using the estimand framework in anesthesia trials to clarify treatment effects, address common intercurrent events, and ensure results are relevant to clinical questions.
Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial.
Trials
March 2024
UCSF Center for Tuberculosis, University of California, San Francisco, San Francisco, CA, USA.
Background: Randomized trials for the treatment of tuberculosis (TB) rely on a composite primary outcome to capture unfavorable treatment responses. However, variability between trials in the outcome definition and estimation methods complicates across-trial comparisons and hinders the advancement of treatment guidelines. The International Council for Harmonization (ICH) provides international regulatory standards for clinical trials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!